ASN-RASAGILINE TABLET
国家: 加拿大
语言: 英文
来源: Health Canada
产品特点
(SPC)
03-05-2019
该产品的某些文档当前不可用，您可以向我们的客户服务发送请求，我们将在获得它们后尽快通知您。
发送请求。
发送请求。
有效成分:
RASAGILINE (RASAGILINE MESYLATE)
可用日期:
ASCEND LABORATORIES LTD
ATC代码:
N04BD02
INN（国际名称）:
RASAGILINE
剂量:
1MG
药物剂型:
TABLET
组成:
RASAGILINE (RASAGILINE MESYLATE) 1MG
给药途径:
ORAL
每包单位数:
100
处方类型:
Prescription
治疗领域:
MONOAMINE OXIDASE B INHIBITORS
產品總結:
Active ingredient group (AIG) number: 0151662002; AHFS:
授权状态:
APPROVED
授权日期:
2019-06-04
产品特点
PRODUCT MONOGRAPH
Pr
ASN-RASAGILINE
RASAGILINE MESYLATE
0.5 MG AND 1 MG RASAGILINE TABLETS (AS RASAGILINE MESYLATE)
ANTIPARKINSON AGENT
Ascend Laboratories Ltd.
35 Nixon Road, Unit 10
Caledon, Ontario
L7E 1K1
Date of Preparation:
May 30, 2019
Control Number: 221339
2
TABLE OF CONTENTS
PART I: HEALTH PROFESSIONAL INFORMATION
.........................................................3
SUMMARY PRODUCT INFORMATION
........................................................................3
INDICATIONS AND CLINICAL USE
..............................................................................3
CONTRAINDICATIONS
...................................................................................................3
WARNINGS AND PRECAUTIONS
..................................................................................4
ADVERSE REACTIONS
..................................................................................................10
DRUG INTERACTIONS
..................................................................................................15
DOSAGE AND ADMINISTRATION
..............................................................................16
OVERDOSAGE
................................................................................................................18
ACTION AND CLINICAL PHARMACOLOGY
............................................................19
STORAGE AND STABILITY
..........................................................................................21
DOSAGE FORMS, COMPOSITION AND PACKAGING
.............................................21
PART II: SCIENTIFIC INFORMATION
...............................................................................23
PHARMACEUTICAL INFORMATION
..........................................................................23
CLINICAL TRIALS
..........................................................................................................23
DETAILED PHARMACOLOGY
.....................................................................................28
T
阅读完整的文件
